SCHEMBL2203256

SCHEMBL2203256

C=CCCC(C(=O)OCC)C(=O)OCC

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 6/20 0.43
MAPK1 P28482 3/20 0.43
TDP1 Q9NUW8 5/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 7/20 0.41
LMNA P02545 5/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 1/20 0.39
USP2 O75604 2/20 0.37
CYP3A4 P08684 2/20 0.37
MAPT P10636 2/20 0.37
RECQL P46063 1/20 0.37
TSHR P16473 3/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL6824986 0.96 L3MBTL1 (0.42) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL6664974 0.92 L3MBTL1 (0.39) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL8342772 0.92 TDP1 (0.39) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL28174502 0.89 L3MBTL1 (0.39) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL2207325 0.88 L3MBTL1 (0.48) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL28180555 0.88 TDP1 (0.43) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL28162464 0.88 TSHR (0.47) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL28168242 0.87 PLA2G2C (0.47) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL6067595 0.86 L3MBTL1 (0.47) L3MBTL1MAPK1TDP1MEN1KMT2A
SCHEMBL7074449 0.85 MAPT (0.49) L3MBTL1MAPK1TDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2001013742-A1 ETHYL HEX-5-ENOATE AS A FLAVORING AGENT AND METHODS FOR PREPARING AND USING SAME BUSH BOAKE ALLEN INC. (US) 2001-03-01 WO claimed
CN-117321046-A Indazole-based compounds and related methods of use 阿维纳斯企业公司 2023-12-29 CN disclosed
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
US-10544244-B2 Bridged biphenyl phenol transition metal complexes, production and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-01-28 US disclosed
CN-110407730-A Pyrrolidones herbicide FMC CORP 2019-11-05 CN disclosed
CN-106414403-B Pyrrolidinone herbicides FMC公司 2019-08-30 CN disclosed
CN-109844036-A Crude oil ester and cyanoacrylate base concrete surface sealer 泽菲罗斯有限公司 2019-06-04 CN disclosed
CN-109641237-A The acid catalyzed curable coating composition and relevant coating and method of vinyl compound containing 1,1- bis--activation PPG工业俄亥俄公司 2019-04-16 CN disclosed
US-20190040165-A1 Bridged Biphenyl Phenol Transition Metal Complexes, Production and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2019-02-07 US disclosed
WO-2019027572-A1 BRIDGED BIPHENYL PHENOL TRANSITION METAL COMPLEXES, PRODUCTION, AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2019-02-07 WO disclosed
US-20040142945-A1 Fused heterocyclic compounds and use thereof BRISTOL-MYERS SQUIBB COMPANY 2004-07-22 US disclosed
WO-2004043367-A2 FUSED HETEROCYCLIC COMPOUNDS AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 WO disclosed
WO-2001013742-A1 ETHYL HEX-5-ENOATE AS A FLAVORING AGENT AND METHODS FOR PREPARING AND USING SAME BUSH BOAKE ALLEN INC. (US) 2001-03-01 WO disclosed
EP-0666262-B1 Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same CANON KK (JP) 2000-08-30 EP disclosed
EP-0866705-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-03-03 EP disclosed
US-5852045-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-22 US disclosed
US-5849217-A Optically active compound, liquid crystal composition containing the same, liquid crystal device using the same, liquid crystal apparatus and display method CANON KABUSHIKI KAISHA (JP) 1998-12-15 US disclosed
EP-0866705-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-09-30 EP disclosed
WO-1997014417-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-04-24 WO disclosed
EP-0666262-A1 Optically active compound, liquid crystal containing the same, liquid crystal device and display method using the same CANON KABUSHIKI KAISHA (JP) 1995-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142945-A1 Fused heterocyclic compounds and use thereof MCL1, NFATC1, BCR L3MBTL1 1627/4885MAPK1 1107/4885TDP1 2352/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 L3MBTL1 243/4885MAPK1 2363/4885TDP1 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.